Mark Coleman - May 28, 2024 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Role
Director
Signature
/s/ Herriot Tabuteau, M.D., Attorney-in-Fact
Stock symbol
AXSM
Transactions as of
May 28, 2024
Transactions value $
-$789,107
Form type
4
Date filed
5/29/2024, 08:11 PM
Previous filing
Sep 15, 2023
Next filing
Jun 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Sale -$395K -5.25K -20.91% $75.21 19.8K May 28, 2024 Direct F1, F2, F3
transaction AXSM Common Stock Sale -$394K -5.25K -26.44% $75.14 14.6K May 29, 2024 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Such transaction was pursuant to a pre-approved 10b5-1 plan.
F2 Represents the sale of underlying shares of previously exercised stock options.
F3 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $75.00 and $75.88.
F4 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $75.00 and $75.90.